COMP <GO>
CLDX vs NEOG // EV/EBITDA & P/E VALUATION
Celldex Therapeutics Inc. (NASDAQ) VS. Neogen Corporation (NASDAQ) • 15-METRIC TALLY: CLDX 3
— NEOG 7
■ METRIC PARITY
LAST: $29.89 (+0.78%) • MKT CAP: $2.35B
valuation
—
LAST: $12.26 (+1.16%) • MKT CAP: $2.68B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLDX VS. NEOG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLDX | NEOG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.10% | 46.90% | +40.20 | CLDX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -0.60% | -34.40 | NEOG | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.10% | 3.11% | -12.21 | NEOG | /fcf-yield <GO> |
| Operating Margin | -60.00% | -2.50% | -57.50 | NEOG | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -0.90% | -59.10 | NEOG | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | -2.70% | -62.30 | NEOG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 20.25 | 1.45 | +18.80 | CLDX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | NEOG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.5 | 45.3 | +0.20 | CLDX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.35B | $2.68B | -$329.2M | NEOG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLDX REV | NEOG REV | CLDX GROSS % | NEOG GROSS % | CLDX FCF | NEOG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.5M | $870.4M | 87.1% | 46.9% | -$213.7M | $83.2M |
| FY 2024 | $7.0M | $894.7M | 97.2% | 47.1% | -$159.7M | $58.2M |
| FY 2023 | $6.9M | $924.2M | — | — | -$107.3M | $35.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLDX // BETA —
NEOG // BETA —